PL2467387T3 - Tricykliczne związki heterocykliczne jako inhibitory kinazy 3-fosfoinozytydu - Google Patents
Tricykliczne związki heterocykliczne jako inhibitory kinazy 3-fosfoinozytyduInfo
- Publication number
- PL2467387T3 PL2467387T3 PL10747483T PL10747483T PL2467387T3 PL 2467387 T3 PL2467387 T3 PL 2467387T3 PL 10747483 T PL10747483 T PL 10747483T PL 10747483 T PL10747483 T PL 10747483T PL 2467387 T3 PL2467387 T3 PL 2467387T3
- Authority
- PL
- Poland
- Prior art keywords
- phosphoinositide
- kinase inhibitors
- heterocyclic compounds
- tricyclic heterocyclic
- tricyclic
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0914594A GB0914594D0 (en) | 2009-08-20 | 2009-08-20 | Compounds |
| GBGB1005584.6A GB201005584D0 (en) | 2010-04-01 | 2010-04-01 | Compounds |
| EP10747483.5A EP2467387B1 (en) | 2009-08-20 | 2010-08-19 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors. |
| PCT/GB2010/051370 WO2011021038A1 (en) | 2009-08-20 | 2010-08-19 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2467387T3 true PL2467387T3 (pl) | 2015-08-31 |
Family
ID=42756474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10747483T PL2467387T3 (pl) | 2009-08-20 | 2010-08-19 | Tricykliczne związki heterocykliczne jako inhibitory kinazy 3-fosfoinozytydu |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US9200007B2 (enExample) |
| EP (1) | EP2467387B1 (enExample) |
| JP (1) | JP5746172B2 (enExample) |
| CN (1) | CN102498115B (enExample) |
| AU (1) | AU2010286168B2 (enExample) |
| BR (1) | BR112012003955A2 (enExample) |
| CA (1) | CA2771594C (enExample) |
| ES (1) | ES2534326T3 (enExample) |
| IL (1) | IL217903A (enExample) |
| IN (1) | IN2012DN01325A (enExample) |
| MX (1) | MX2012002059A (enExample) |
| NZ (1) | NZ597983A (enExample) |
| PL (1) | PL2467387T3 (enExample) |
| WO (1) | WO2011021038A1 (enExample) |
| ZA (1) | ZA201200910B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ597983A (en) | 2009-08-20 | 2014-05-30 | Karus Therapeutics Ltd | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
| BR112013014914B8 (pt) * | 2010-12-16 | 2020-08-04 | Hoffmann La Roche | composto, composição farmacêutica e uso de um composto |
| AU2015268776B2 (en) * | 2010-12-16 | 2017-04-13 | Genentech, Inc. | Tricyclic PI3k inhibitor compounds and methods of use |
| PL2790705T3 (pl) | 2011-12-15 | 2018-06-29 | Novartis Ag | Zastosowanie inhibitorów czynności lub funkcji PI3K |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| KR102127406B1 (ko) | 2012-09-20 | 2020-06-29 | 유디씨 아일랜드 리미티드 | 전자 응용을 위한 아자디벤조푸란 |
| EP2917202B1 (en) | 2012-11-07 | 2018-05-02 | Karus Therapeutics Limited | Novel histone deacetylase inhibitors and their use in therapy |
| JP6434416B2 (ja) | 2012-11-08 | 2018-12-05 | ライゼン・ファーマシューティカルズ・エスアー | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物 |
| AR095443A1 (es) * | 2013-03-15 | 2015-10-14 | Fundación Centro Nac De Investig Oncológicas Carlos Iii | Heterociclos condensados con acción sobre atr |
| CN105358550B (zh) | 2013-05-10 | 2018-04-06 | 卡鲁斯治疗有限公司 | 组蛋白脱乙酰基酶抑制剂 |
| US9814037B2 (en) * | 2013-06-28 | 2017-11-07 | Intel Corporation | Method for efficient channel estimation and beamforming in FDD system by exploiting uplink-downlink correspondence |
| CN104557955B (zh) * | 2013-10-23 | 2017-05-03 | 上海汇伦生命科技有限公司 | 作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途 |
| GB201402431D0 (en) * | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201514754D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514756D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compound and method of use |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| ES2907574T3 (es) | 2015-12-16 | 2022-04-25 | Genentech Inc | Proceso para la preparación de compuestos inhibidores de pi3k triciclicos y métodos para su utilización para el tratamiento del cáncer. |
| KR102474326B1 (ko) | 2016-06-22 | 2022-12-05 | 반더빌트유니버시티 | 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| EP3558309B1 (en) | 2016-11-07 | 2023-07-26 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| ES2892956T3 (es) | 2016-11-07 | 2022-02-07 | Univ Vanderbilt | Moduladores alostéricos positivos del receptor muscarínico de acetilcolina M4 |
| US11008335B2 (en) | 2016-11-07 | 2021-05-18 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
| GB201702938D0 (en) | 2017-02-23 | 2017-04-12 | Univ Southampton | Methods of generating and screening compartmentalised peptides libraries |
| CN111406058A (zh) | 2017-12-05 | 2020-07-10 | 范德比尔特大学 | 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂 |
| TW201930311A (zh) | 2017-12-05 | 2019-08-01 | 泛德比爾特大學 | 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑 |
| SG11202005785XA (en) | 2018-01-10 | 2020-07-29 | Recurium Ip Holdings Llc | Benzamide compounds |
| WO2022169882A1 (en) | 2021-02-03 | 2022-08-11 | Verge Analytics, Inc. | Methods and treatment of viral infection caused by sars-cov-2 |
| CN117751127A (zh) * | 2021-08-20 | 2024-03-22 | 南京大美生物制药有限公司 | 一种五元含氮杂环并杂芳基类衍生物及其用途 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1445742A1 (de) | 1963-11-06 | 1968-12-19 | Bayer Ag | Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen |
| US4017500A (en) | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
| US5703075A (en) | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| WO2001083456A1 (en) | 2000-04-27 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Condensed heteroaryl derivatives |
| US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| WO2002002551A1 (en) | 2000-06-30 | 2002-01-10 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| EP1521747B1 (en) | 2002-07-15 | 2018-09-05 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
| FR2846657B1 (fr) | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CN1922171B (zh) | 2004-02-26 | 2012-10-17 | Aska制药株式会社 | 嘧啶衍生物 |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| ES2380795T3 (es) | 2005-05-20 | 2012-05-18 | Vertex Pharmaceuticals, Inc. | Pirrolopiridinas útiles como inhibidores de proteínas quinasas |
| EP1979353A2 (en) | 2006-01-19 | 2008-10-15 | OSI Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
| CA2650196A1 (en) * | 2006-04-26 | 2007-11-01 | Stewart James Baker | Pyrimidine derivatives as pi3k inhibitors |
| TW200801012A (en) * | 2006-04-26 | 2008-01-01 | Piramed Ltd | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| EP2035436B1 (en) | 2006-06-26 | 2011-05-25 | UCB Pharma S.A. | Fused thiazole derivatives as kinase inhibitors |
| EP2097422A4 (en) | 2006-11-13 | 2010-04-14 | Lilly Co Eli | THIENOPYRIMIDINONE FOR THE TREATMENT OF INFLAMMATORY DISEASES AND CARCINOMAS |
| CA2677096A1 (en) | 2007-01-31 | 2008-08-07 | Vertex Pharmaceuticals Incorporated | Kinase inhibitors |
| EP2139332A4 (en) | 2007-03-28 | 2010-04-21 | Merck Sharp & Dohme | SUBSTITUTED PYRIDO [2,3-D] PYRIMIDIN DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS |
| JP2010529031A (ja) | 2007-05-29 | 2010-08-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体 |
| GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| US9029411B2 (en) * | 2008-01-25 | 2015-05-12 | Millennium Pharmaceuticals, Inc. | Thiophenes and uses thereof |
| WO2010015520A1 (de) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Substituierte naphthyridine und ihre verwendung als arzneimittel |
| WO2010037765A2 (en) | 2008-10-03 | 2010-04-08 | Merck Serono S.A. | 4-morpholino-pyrido[3,2-d]pyrimidines |
| GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| US8981087B2 (en) | 2009-07-29 | 2015-03-17 | Karus Therapeutics Limited | Benzo [E] [1,3] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors |
| NZ597983A (en) | 2009-08-20 | 2014-05-30 | Karus Therapeutics Ltd | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
| US20110207736A1 (en) | 2009-12-23 | 2011-08-25 | Gatekeeper Pharmaceuticals, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| GB201007347D0 (en) | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
| EP3333161B1 (en) | 2011-07-27 | 2020-02-19 | Astrazeneca AB | 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer |
| WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| BR112015011456A2 (pt) | 2012-11-20 | 2017-07-11 | Genentech Inc | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m |
| CN105358550B (zh) | 2013-05-10 | 2018-04-06 | 卡鲁斯治疗有限公司 | 组蛋白脱乙酰基酶抑制剂 |
| US20140377258A1 (en) | 2013-05-30 | 2014-12-25 | Infinity Pharmaceuticals, Inc. | Treatment Of Cancers Using PI3 Kinase Isoform Modulators |
| WO2014210354A1 (en) | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| JP6584391B2 (ja) | 2013-10-10 | 2019-10-02 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｐｉ３ｋ阻害剤との組み合わせ |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321730D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321728D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| GB201514756D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compound and method of use |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
-
2010
- 2010-08-19 NZ NZ597983A patent/NZ597983A/en not_active IP Right Cessation
- 2010-08-19 US US13/388,164 patent/US9200007B2/en active Active
- 2010-08-19 IN IN1325DEN2012 patent/IN2012DN01325A/en unknown
- 2010-08-19 CN CN201080036402.7A patent/CN102498115B/zh active Active
- 2010-08-19 WO PCT/GB2010/051370 patent/WO2011021038A1/en not_active Ceased
- 2010-08-19 BR BR112012003955A patent/BR112012003955A2/pt not_active Application Discontinuation
- 2010-08-19 CA CA2771594A patent/CA2771594C/en not_active Expired - Fee Related
- 2010-08-19 ES ES10747483.5T patent/ES2534326T3/es active Active
- 2010-08-19 MX MX2012002059A patent/MX2012002059A/es active IP Right Grant
- 2010-08-19 AU AU2010286168A patent/AU2010286168B2/en not_active Ceased
- 2010-08-19 JP JP2012525212A patent/JP5746172B2/ja active Active
- 2010-08-19 PL PL10747483T patent/PL2467387T3/pl unknown
- 2010-08-19 EP EP10747483.5A patent/EP2467387B1/en active Active
-
2012
- 2012-02-02 IL IL217903A patent/IL217903A/en active IP Right Grant
- 2012-02-07 ZA ZA2012/00910A patent/ZA201200910B/en unknown
-
2015
- 2015-10-22 US US14/920,410 patent/US9580442B2/en active Active
-
2017
- 2017-01-19 US US15/410,114 patent/US9938290B2/en active Active
-
2018
- 2018-03-01 US US15/909,011 patent/US10501478B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102498115B (zh) | 2016-12-07 |
| EP2467387B1 (en) | 2015-01-07 |
| BR112012003955A2 (pt) | 2017-09-26 |
| NZ597983A (en) | 2014-05-30 |
| EP2467387A1 (en) | 2012-06-27 |
| US20120178737A1 (en) | 2012-07-12 |
| IL217903A0 (en) | 2012-03-29 |
| CA2771594A1 (en) | 2011-02-24 |
| IL217903A (en) | 2017-08-31 |
| US9580442B2 (en) | 2017-02-28 |
| US20180009826A1 (en) | 2018-01-11 |
| WO2011021038A1 (en) | 2011-02-24 |
| US9200007B2 (en) | 2015-12-01 |
| IN2012DN01325A (enExample) | 2015-06-05 |
| AU2010286168B2 (en) | 2014-05-15 |
| US9938290B2 (en) | 2018-04-10 |
| CN102498115A (zh) | 2012-06-13 |
| US20160108057A1 (en) | 2016-04-21 |
| JP2013502404A (ja) | 2013-01-24 |
| AU2010286168A1 (en) | 2012-03-08 |
| ZA201200910B (en) | 2013-05-29 |
| US20190040079A1 (en) | 2019-02-07 |
| JP5746172B2 (ja) | 2015-07-08 |
| US10501478B2 (en) | 2019-12-10 |
| MX2012002059A (es) | 2012-04-19 |
| CA2771594C (en) | 2018-05-01 |
| ES2534326T3 (es) | 2015-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2467387T3 (pl) | Tricykliczne związki heterocykliczne jako inhibitory kinazy 3-fosfoinozytydu | |
| IL295518B1 (en) | Heterocyclic compounds used as pdk1 inhibitors | |
| IL261778A (en) | New tricyclic compounds | |
| ZA201201124B (en) | Heterocyclic compounds as autotaxin inhibitors | |
| IL215258A0 (en) | Heterocyclic compounds as autotaxin inhibitors | |
| IL216145A0 (en) | Dihydropyrimidinones for use as bace2 inhibitors | |
| IL239081B (en) | Benzoxazepine pi3k inhibitor compound | |
| IL218292A0 (en) | Heterocyclic compounds for the inhibition of pask | |
| IL220053A0 (en) | Novel tricyclic compounds | |
| IL219385A0 (en) | N-containing heteroayl derivatives as kaj3 kinase inhibitors | |
| IL200934A0 (en) | Spiro substituted compounds as angiogenesis inhibitors | |
| IL200854A0 (en) | Spiro substituted compounds as angiogenesis inhibitors | |
| IL218271A0 (en) | Heterocyclic compounds as janus kinase inhibitors | |
| ZA201103476B (en) | Heterocyclically substituted aryl compounds as hif inhibitors | |
| AP2010005364A0 (en) | Novel heterocyclic compounds. | |
| IL220701A0 (en) | Tricyclic compounds for use as kinase inhibitors | |
| IL220205A0 (en) | Heterocyclic compounds as janus kinase inhibitors | |
| EP2379538A4 (en) | HETEROCYCLIC COMPOUNDS AS A PHOSOPHODIESTERASE HEMMER | |
| IL213935A0 (en) | Novel heterocyclic compounds as metap-2 inhibitors | |
| HK1178150A (en) | Tricyclic compounds for use as kinase inhibitors | |
| GB0919817D0 (en) | Heterocyclic compounds | |
| GB0919816D0 (en) | Heterocyclic compounds |